AstraZeneca has reported positive results from the Phase III FLAURA trial of Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).

The trial has met the primary endpoint of statistically significant and clinically meaningful progression-free survival (PFS) in previously untreated patients who were epidermal growth factor receptor mutation (EGFRm) positive.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tagrisso is an irreversible EGFR tyrosine kinase inhibitor (TKI) currently being developed to inhibit EGFR sensitising and EGFR T790M resistance mutations.

The double-blinded, randomised Phase III trial compared the efficacy and safety of 80mg once-daily Tagrisso with standard-of-care EGFR-TKIs, oral once-daily 150mg of erlotinib and 250mg once-daily oral gefitinib in a total of 556 subjects across 30 countries.

"We will now initiate discussions with global health authorities on the data and regulatory submissions."

AstraZeneca global medicines development executive vice-president and chief medical officer Sean Bohen said: “The strong results from the FLAURA trial are very exciting news for patients with EGFR mutation-positive non-small-cell lung cancer, providing physicians with a potential new first-line treatment option to improve outcomes in this disease.

See Also:

“We will now initiate discussions with global health authorities on the data and regulatory submissions.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FLAURA trial’s primary endpoint was PFS, while secondary endpoints comprised safety, overall survival, objective response rate, duration of response, disease control rate and measures of health-related quality of life (HRQoL).

During the trial period, the efficacy, safety and tolerability of Tagrisso, erlotinib and gefitinib were observed to be consistent with their documented profiles.

AstraZeneca also reported that the combination of its Imfinzi with tremelimumab did not meet the primary endpoint during interim analysis of the Phase III MYSTIC trial conducted in collaboration with MedImmune for previously untreated metastatic first-line NSCLC patients.